By Matt Harrington, BCBA · Behaviorist Book Club · Research-backed answers for behavior analysts
A fad treatment achieves widespread clinical or family adoption without adequate empirical support — specifically without controlled experimental evaluation demonstrating a functional relationship between the treatment and meaningful outcomes. Key characteristics include: popularity driven by testimonials, social media, or commercial promotion rather than peer-reviewed evidence; mechanism claims that are implausible or untested; absence of replication in controlled studies; and resistance to negative findings among proponents. Some fad treatments are simply unstudied; others have been studied and found ineffective. Both categories require the same ethical response from BCBAs under Code 2.01.
Code 2.01 requires behavior analysts to use scientifically supported procedures and to provide services within defined areas of established knowledge. Code 5.04 requires following the most stringent applicable ethics standard when institutional requirements conflict with the Ethics Code — meaning an employer directive to implement a fad treatment does not override the BCBA's ethical obligation. The appropriate response is to raise the concern through professional channels, document the conversation, and consult with a supervisor or ethics resource. BCBAs should not implement treatments they have evaluated as non-evidence-based simply because of institutional or family pressure.
Effective communication starts with acknowledging the family's hope and the genuine desire to help their child — the emotional investment in a fad treatment is understandable and worthy of respect. Follow with an honest account of what the evidence shows, avoiding jargon and framing the evidence review as a shared process rather than an expert ruling. Distinguish between 'not yet studied' and 'studied and found ineffective,' as these require different conversations. Avoid framing that positions the BCBA as withholding something the child needs; instead, frame evidence-based practice as a way of using limited time and resources most effectively.
The supervisor bears responsibility for ensuring supervisees understand and follow the Ethics Code, including Code 2.01's requirement to use scientifically supported procedures. If a supervisee is implementing a fad treatment — whether under instruction from the organization or from a family request — the supervisor should address this directly in supervision, review the evidence base together, and ensure the supervisee understands the ethical obligation and how to navigate it. If the fad treatment is an organizational policy, the supervisor has an additional obligation under Code 7.01 to advocate for evidence-based practice through appropriate organizational channels.
Adequate evidence for an ABA intervention typically includes: replicated single-case experimental designs with appropriate experimental controls, published in peer-reviewed journals; or randomized controlled trials when the intervention is suitable for group designs. Evaluate the quality of experimental control — does the study demonstrate a functional relationship or merely a correlation? Check whether outcomes are measured with objective, observable dependent variables. Assess replication: a single study is never sufficient. Be alert to surrogate endpoints (measuring a proxy rather than the clinical outcome of interest) and to industry-funded studies without independent replication.
BCBAs in interdisciplinary ASD settings frequently encounter facilitated communication and related approaches (such as rapid prompting method / spelling to communicate), sensory integration therapy in forms that go beyond OT evidence, auditory integration training, various dietary interventions (GFCF diets, supplements), hyperbaric oxygen therapy, and educational software or hardware marketed with unsubstantiated outcome claims. The specific landscape shifts over time as new treatments gain social media traction. BCBAs should maintain current awareness of the treatments circulating in their regional or specialty practice community.
Opportunity cost — the evidence-based services not received because resources are devoted to ineffective treatments — is a clinically relevant harm that BCBAs can raise in conversations with families. This is particularly important during developmental periods when intensive early behavioral intervention has documented effects, because time is not recoverable. When communicating about opportunity cost, frame the concern as ensuring the child benefits from the most effective use of available time and resources, not as preventing the family from pursuing their choice. Document this conversation in clinical records as part of the informed consent process.
When a colleague from another discipline — an occupational therapist, psychologist, or SLP — advocates for a fad treatment in a team context, the BCBA's role is to provide an honest account of the evidence without positioning themselves as the sole arbiter of what constitutes valid research. Acknowledge that different disciplines have different evidentiary traditions. Present specific methodological criteria for what constitutes adequate evidence in behavior analysis and why those criteria exist. Offer to review the evidence together. The goal is interdisciplinary dialogue that improves team practice, not a hierarchy of disciplines with behavior analysis at the top.
Effective supervision for fad treatment navigation includes: reviewing specific fad treatments together using a structured evidence evaluation framework; role-playing difficult conversations with families or colleagues; discussing the BCBA's own experiences navigating these situations, including both successes and missteps; reviewing Ethics Code provisions and how they apply to specific scenarios; and analyzing case studies involving practitioners who implemented or failed to object to non-evidence-based treatments and the consequences that followed. These activities build the behavioral fluency and ethical reasoning that trainees need for situations where the path of least resistance conflicts with professional obligation.
A BCBA directed by an employer to implement a non-evidence-based treatment should first raise the concern directly with the supervisor or clinical director, documenting the conversation. If informal resolution fails, consult the organization's ethics resources or a trusted external consultation relationship. Code 5.04 requires following the most stringent applicable ethical standard, meaning the BACB Ethics Code takes precedence over employer directives in this situation. If the organization continues to require implementation despite the BCBA's documented objection, the practitioner may need to seek employment elsewhere — an outcome that Code 5.04 effectively sanctions as the appropriate resolution when ethics conflicts with institutional requirements cannot be resolved.
The ABA Clubhouse has 60+ on-demand CEUs including ethics, supervision, and clinical topics like this one. Plus a new live CEU every Wednesday.
Ready to go deeper? This course covers this topic with structured learning objectives and CEU credit.
The Crossroads Part 1 | Supervision | 1 Hour — Autism Partnership Foundation · 1 BACB General CEUs · $0
Take This Course →1 BACB General CEUs · $0 · Autism Partnership Foundation
Research-backed educational guide with practice recommendations
Side-by-side comparison with clinical decision framework
All behavior-analytic intervention is individualized. The information on this page is for educational purposes and does not constitute clinical advice. Treatment decisions should be informed by the best available published research, individualized assessment, and obtained with the informed consent of the client or their legal guardian. Behavior analysts are responsible for practicing within the boundaries of their competence and adhering to the BACB Ethics Code for Behavior Analysts.